Inhibition of potassium-evoked release of cholecystokinin from rat caudate-putamen, cerebral cortex and hippocampus incubated in vitro by phencyclidine and related compounds.
Potassium-evoked release of cholecystokinin (CCK) from slices of caudate-putamen, hippocampus, and cerebral cortex was inhibited in a dose-related fashion by phencyclidine (PCP). In order to further examine this effect, PCP-like ligands (dexoxadrol, levoxadrol, PCMP and MK-801) as well as compounds known to interact with the sigma receptor ((+)-SKF, DTG, (+)-3-PPP, and pentazocine) were tested. While some of these compounds inhibited CCK release, their rank order potency (Dex = Lev greater than PCP = PCMP greater than DTG = MK-801 = (+)-3-PPP) differs from that of known PCP-N-methyl-D-aspartate linked effects or sigma interactions. These results suggest that the mechanism by which PCP acts to inhibit CCK release may involve a novel type of PCP interaction.
Allard
L R
LR
Department of Pharmacology, St. Louis University Medical School, MO 63104.
Brog
J S
JS
Viereck
J C
JC
Contreras
P C
PC
Jacobson
A E
AE
Rice
K C
KC
Beinfeld
M C
MC
D000818:Animals; D002421:Caudate Nucleus / Q000187:drug effects; D002540:Cerebral Cortex / Q000187:drug effects; D002766:Cholecystokinin / Q000378:metabolism*; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D010622:Phencyclidine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D011188:Potassium / Q000037:antagonists & inhibitors*; D011699:Putamen / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000187:drug effects; D017480:Receptors, sigma; D013687:Telencephalon / Q000187:drug effects* / Q000378:metabolism
D011957:Receptors, Opioid; D017480:Receptors, sigma; D002766:Cholecystokinin; D010622:Phencyclidine; D011188:Potassium